Учёные научились готовить персональные вакцины для борьбы с раком

[valplo]

Круто. К вопросу, кстати, о редактировании ДНК.

[DemetrNieA]

А можно ссылку?

[a5b]

В новости www.bbc.co.uk/news/health-32162799 Personal cancer vaccine research 'exciting' say experts By James Gallagher, Health editor, BBC News website 3 April 2015

Personalised vaccines were given to three patients with advanced tumours in 2013. All had already been treated with another therapy — ipilimumab.
One was in remission and has stayed cancer-free; another still has stable tumours; and the third patient's tumour shrank in the months after the vaccine before returning to its original size and remaining stable.

упоминается научная статья (платный источник; полный текст могу выслать по запросу)
www.sciencemag.org/content/early/2015/04/01/science.aaa3828 Science DOI: 10.1126/science.aaa3828
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Beatriz M. Carreno, (Department of Medicine, Division of Oncology, Washington University School of Medicine) et al. April 2 2015

T cell immunity directed against tumor-encoded amino acid substitutions (AAS) occurs in some melanoma patients. This implicates missense mutations (MM) as a source of patient-specific neoantigens.… Here we show that a dendritic cell vaccine increased naturally occurring and revealed new HLA class I-restricted neoantigens in patients with advanced melanoma.… Our results demonstrate that vaccination directed at tumor AAS broadens the antigenic breadth and clonal diversity of anti-tumor immunity.

Вводные материалы по теме:
neoantigen
en.wikipedia.org/wiki/Tumor_antigen
ru.wikipedia.org/wiki/Опухолевый_антиген
cancerimmunolres.aacrjournals.org/content/1/1/11.full Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines. Cancer Immunol Res; 1(1); 11–15. April 7, 2013; doi: 10.1158/2326-6066.CIR-13-0022
«Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These “neoantigens” should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells.»

[a5b]

> «эта работа открывает путь для персональной иммуно-онкологии»

Стоит отметить, сколько стоил курс более простым (серийным) препаратом MDX-010 — en.wikipedia.org/wiki/Ipilimumab — 120 тысяч долларов США, применявшийся у этих пациентов («All had already been treated with another therapy — ipilimumab.»).